Levy H A, Park C H
Clin Nucl Med. 1987 Apr;12(4):303-7. doi: 10.1097/00003072-198704000-00014.
Nine patients with thyroid cancer were treated with reserpine in an attempt to reduce radiation exposure to the salivary glands from 100-150 mCi doses of I-131 therapy to thyroid remnants or metastases. Three control patients were not treated with reserpine but did receive 100-150 mCi of I-131. Parotid/background ratios of activity after radioablative doses of I-131 in patients not treated with reserpine were significantly higher than the patients treated with reserpine, and this was also true seven days after the radioablative dose. Combined therapy with reserpine, chewing gum, lemon candies, and hydration is suggested for the prevention of sialadenitis and xerostomia due to large doses of radioiodine.
对9例甲状腺癌患者使用利血平进行治疗，旨在将100 - 150毫居里剂量的I - 131用于治疗甲状腺残余组织或转移灶时，减少唾液腺所受的辐射剂量。3例对照患者未接受利血平治疗，但接受了100 - 150毫居里的I - 131。未接受利血平治疗的患者在接受放射性消融剂量的I - 131后，腮腺/本底活性比显著高于接受利血平治疗的患者，在放射性消融剂量后7天也是如此。建议采用利血平、口香糖、柠檬糖和补水联合治疗，以预防大剂量放射性碘导致的涎腺炎和口干症。
